These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 29777274)

  • 1. The natural agent 4-vinylphenol targets metastasis and stemness features in breast cancer stem-like cells.
    Leung HW; Ko CH; Yue GG; Herr I; Lau CB
    Cancer Chemother Pharmacol; 2018 Aug; 82(2):185-197. PubMed ID: 29777274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baicalein suppresses metastasis of breast cancer cells by inhibiting EMT via downregulation of SATB1 and Wnt/β-catenin pathway.
    Ma X; Yan W; Dai Z; Gao X; Ma Y; Xu Q; Jiang J; Zhang S
    Drug Des Devel Ther; 2016; 10():1419-41. PubMed ID: 27143851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4.
    McClements L; Annett S; Yakkundi A; O'Rourke M; Valentine A; Moustafa N; Alqudah A; Simões BM; Furlong F; Short A; McIntosh SA; McCarthy HO; Clarke RB; Robson T
    BMC Cancer; 2019 Apr; 19(1):351. PubMed ID: 30975104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct inhibition of ACTN4 by ellagic acid limits breast cancer metastasis via regulation of β-catenin stabilization in cancer stem cells.
    Wang N; Wang Q; Tang H; Zhang F; Zheng Y; Wang S; Zhang J; Wang Z; Xie X
    J Exp Clin Cancer Res; 2017 Dec; 36(1):172. PubMed ID: 29197410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast cancer stem cell selectivity of synthetic nanomolar-active salinomycin analogs.
    Huang X; Borgström B; Kempengren S; Persson L; Hegardt C; Strand D; Oredsson S
    BMC Cancer; 2016 Feb; 16():145. PubMed ID: 26906175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.
    Serrano-Oviedo L; Nuncia-Cantarero M; Morcillo-Garcia S; Nieto-Jimenez C; Burgos M; Corrales-Sanchez V; Perez-Peña J; Győrffy B; Ocaña A; Galán-Moya EM
    Cell Oncol (Dordr); 2020 Jun; 43(3):431-444. PubMed ID: 32166583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. WM130 preferentially inhibits hepatic cancer stem-like cells by suppressing AKT/GSK3β/β-catenin signaling pathway.
    Ni CX; Qi Y; Zhang J; Liu Y; Xu WH; Xu J; Hu HG; Wu QY; Wang Y; Zhang JP
    Oncotarget; 2016 Nov; 7(48):79544-79556. PubMed ID: 27783993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aryl hydrocarbon receptor/cytochrome P450 1A1 pathway mediates breast cancer stem cells expansion through PTEN inhibition and β-Catenin and Akt activation.
    Al-Dhfyan A; Alhoshani A; Korashy HM
    Mol Cancer; 2017 Jan; 16(1):14. PubMed ID: 28103884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Silibinin inhibits β-catenin/ZEB1 signaling and suppresses bladder cancer metastasis via dual-blocking epithelial-mesenchymal transition and stemness.
    Wu K; Ning Z; Zeng J; Fan J; Zhou J; Zhang T; Zhang L; Chen Y; Gao Y; Wang B; Guo P; Li L; Wang X; He D
    Cell Signal; 2013 Dec; 25(12):2625-33. PubMed ID: 24012496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MiR-21 regulates epithelial-mesenchymal transition phenotype and hypoxia-inducible factor-1α expression in third-sphere forming breast cancer stem cell-like cells.
    Han M; Wang Y; Liu M; Bi X; Bao J; Zeng N; Zhu Z; Mo Z; Wu C; Chen X
    Cancer Sci; 2012 Jun; 103(6):1058-64. PubMed ID: 22435731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CCL16 maintains stem cell-like properties in breast cancer by activating CCR2/GSK3β/β-catenin/OCT4 axis.
    Shen W; Zhang X; Tang J; Zhang Z; Du R; Luo D; Liu X; Xia Y; Li Y; Wang S; Yan S; Yang W; Xiang R; Luo N; Luo Y; Li J
    Theranostics; 2021; 11(5):2297-2317. PubMed ID: 33500726
    [No Abstract]   [Full Text] [Related]  

  • 12. Monospecific antibody targeting of CDH11 inhibits epithelial-to-mesenchymal transition and represses cancer stem cell-like phenotype by up-regulating miR-335 in metastatic breast cancer, in vitro and in vivo.
    Chen JH; Huang WC; Bamodu OA; Chang PM; Chao TY; Huang TH
    BMC Cancer; 2019 Jun; 19(1):634. PubMed ID: 31248373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Caveolin-1 mediates chemoresistance in breast cancer stem cells via β-catenin/ABCG2 signaling pathway.
    Wang Z; Wang N; Li W; Liu P; Chen Q; Situ H; Zhong S; Guo L; Lin Y; Shen J; Chen J
    Carcinogenesis; 2014 Oct; 35(10):2346-56. PubMed ID: 25085904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of a polyphenol-enriched preparation on chemoprevention of mammary carcinoma through cancer stem cells and inflammatory pathways modulation.
    Vuong T; Mallet JF; Ouzounova M; Rahbar S; Hernandez-Vargas H; Herceg Z; Matar C
    J Transl Med; 2016 Jan; 14():13. PubMed ID: 26762586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sulforaphane, a dietary component of broccoli/broccoli sprouts, inhibits breast cancer stem cells.
    Li Y; Zhang T; Korkaya H; Liu S; Lee HF; Newman B; Yu Y; Clouthier SG; Schwartz SJ; Wicha MS; Sun D
    Clin Cancer Res; 2010 May; 16(9):2580-90. PubMed ID: 20388854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. O-Acetyl-GD2 as a Therapeutic Target for Breast Cancer Stem Cells.
    Cheng JY; Hung JT; Lin J; Lo FY; Huang JR; Chiou SP; Wang YH; Lin RJ; Wu JC; Yu J; Yu AL
    Front Immunol; 2021; 12():791551. PubMed ID: 35046949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zoledronic acid inhibits the growth of cancer stem cell derived from cervical cancer cell by attenuating their stemness phenotype and inducing apoptosis and cell cycle arrest through the Erk1/2 and Akt pathways.
    Wang L; Liu Y; Zhou Y; Wang J; Tu L; Sun Z; Wang X; Luo F
    J Exp Clin Cancer Res; 2019 Feb; 38(1):93. PubMed ID: 30791957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dietary compound isoliquiritigenin targets GRP78 to chemosensitize breast cancer stem cells via β-catenin/ABCG2 signaling.
    Wang N; Wang Z; Peng C; You J; Shen J; Han S; Chen J
    Carcinogenesis; 2014 Nov; 35(11):2544-54. PubMed ID: 25194164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel miR-34a target, protein kinase D1, stimulates cancer stemness and drug resistance through GSK3/β-catenin signaling in breast cancer.
    Kim do Y; Park EY; Chang E; Kang HG; Koo Y; Lee EJ; Ko JY; Kong HK; Chun KH; Park JH
    Oncotarget; 2016 Mar; 7(12):14791-802. PubMed ID: 26895471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-148a suppressed cell invasion and migration via targeting WNT10b and modulating β-catenin signaling in cisplatin-resistant colorectal cancer cells.
    Shi L; Xi J; Xu X; Peng B; Zhang B
    Biomed Pharmacother; 2019 Jan; 109():902-909. PubMed ID: 30551544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.